Oosterweld et al. (60) found that CSF and serum NfL levels in combination with CSF α-synuclein species(phosphorylated-/total α-synuclein, and oligomeric-/total α-synuclein) may serve as a biomarker panel for discrimination of PD patients compared with controls. This evidence concerns the gene SNCA and Parkinson disease.